Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

ANEB·NASDAQ

$1.72

-33%
HealthcareBiotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

At a Glance

Live Snapshot
Market Cap$70.67M
EPS-0.2500
P/E Ratio-5.74
Earnings Date02/12/2026

aneb

Total Other Income Expenses Net

Last Annual Value

738.72K

3-Year CAGR

410%

5-Year CAGR

257%

10-Year CAGR

89%

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Competitors Analysis of Total Other Income Expenses Net

ANEB · NASDAQ
CompanyTotal Other Income Expenses Net
CAGR 3Y
CAGR 5Y
CAGR 10Y
738.72K
143.3%N/AN/A 
CLNN logo
Clene Inc.
NASDAQ:CLNN
-3.09M
N/AN/AN/A
-2.19M
N/AN/AN/A
9.63M
13.4%-28.1%N/A
3.51M
-8.1%71.3%9.3%
19.51M
30.0%187.1%N/A
EXOZ logo
eXoZymes, Inc.
NASDAQ:EXOZ
452.53K
N/A40.1%N/A
-44.14M
N/AN/AN/A
90.41M
63.1%151.8%N/A
544.00K
-43.6%7.8%N/A
-2.45M
N/AN/AN/A
Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Fair Value Envelope

ANEB · NASDAQ

Our analysis suggests that ANEB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.72, this represents a potential HIDDEN relative to our calculated worth for Anebulo Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $1.72